Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.42 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.42 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764837 | 0.88 | GPR119 (0.55) | GPR119PDE4BSCD | |
| SCHEMBL16296027 | 0.86 | PIN1 (0.42) | USP30HDAC1HDAC2GPR119PDE4B | |
| SCHEMBL3954269 | 0.85 | USP30 (0.47) | RBP4USP30GPR119CACNB4CACNA1A | |
| SCHEMBL15058459 | 0.84 | SMN1; SMN2 (0.48) | RBP4USP30HDAC1HDAC2GPR119 | |
| SCHEMBL21222585 | 0.84 | PDE4D (0.55) | RBP4USP30HDAC1HDAC2GPR119 | |
| SCHEMBL15058234 | 0.83 | RBP4 (0.45) | RBP4USP30HDAC1HDAC2GPR119 | |
| SCHEMBL2160873 | 0.82 | SCD (0.47) | RBP4SCDPIN1 | |
| SCHEMBL15058619 | 0.81 | GPR119 (0.48) | GPR119SCD | |
| SCHEMBL15058621 | 0.81 | GPR119 (0.48) | GPR119SCD | |
| SCHEMBL15058620 | 0.81 | GPR119 (0.48) | GPR119SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350054-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2011-07-28 | — | — | US | disclosed |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2011-07-28 | — | — | US | disclosed |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2011-07-28 | — | — | US | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | LEBLANC YVES | 2009-10-29 | — | — | US | disclosed |
| US-7582633-B2 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA L.L.C. (CA) | 2009-09-01 | — | — | US | disclosed |
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | RBP4 668/4885USP30 3743/4885HDAC1 563/4885 |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FADS2 | RBP4 725/4885USP30 2823/4885HDAC1 2354/4885 |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RBP4 668/4885USP30 3743/4885HDAC1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.